Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2016
Pharma News, 2016
Lilly Provides Update on MONARCH 2 Phase 3 Trial of Abemaciclib
INDIANAPOLIS, IN, USA - August 10, 2016 - Eli Lilly and Company (NYSE.
New compound shows hope for prostate cancer therapy
Researchers have identified a novel compound that can block testosterone from fuelling the tumours in mice and act as a new generation therapy for prostate cancer.
Valeant looks to sell billions in assets to cut debt, stock soars
Valeant Pharmaceuticals International Inc (VRX.
vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes
HIGH POINT, NC, USA - August 10, 2016 - vTv Therapeutics Inc.
FDA bans a third Wockhardt plant
It's strike three for India’s Wockhardt, which has had a third plant in its home country banned from exporting to the U.
AstraZeneca drug selumetinib fails in lung cancer study
AstraZeneca's cancer drug pipeline suffered a setback on Tuesday when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.
Mesoblast cell treatment shows promise in rheumatoid arthritis : study
Mesoblast Ltd on Monday said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by wi...
AbbVie Sues Amgen to Fend Off Copy of Blockbuster Humira Susan Decker
Biotechnology drugmaker AbbVie Inc.
Allergan PLC (AGN) Releases Earnings Results, Meets Expectations
Allergan PLC (NYSE.
Bristol-Myers' Opdivo fails lung cancer trial; shares plunge
Bristol-Myers Squibb Co said its blockbuster Opdivo immunotherapy failed to slow progression of symptoms in previously untreated patients with advanced lung cancer, a major setback expected to benefit...
Teva agrees to buy Allergan's generics distribution unit
Teva Pharmaceutical Industries agreed to buy a generics distribution company from Allergan for $500 million, the drug makers said Wednesday, a day after Teva completed the purchase of Allergan’s gen...
Keep Calm and Spend On, Regeneron
Investors tend to recoil when a company's expenses jump.
21
22
23
24
25
26
27
28
29
